AI Article Synopsis
- Filoviruses, like ebolaviruses and marburgviruses, can lead to severe and often deadly illnesses in humans.
- Recent advancements in antibody therapy show promise for treating these infections, specifically through two distinct monoclonal antibodies (mAbs) derived from mice given vaccines.
- These mAbs are effective against various ebolaviruses, providing significant protection in animal models, particularly showcasing 100% protection against the Sudan virus when used together.
Article Abstract
Filoviruses, including ebolaviruses and marburgviruses, can cause severe and often fatal disease in humans. Over the past several years, antibody therapy has emerged as a promising strategy for the treatment of filovirus disease. Here, we describe 2 distinct cross-reactive monoclonal antibodies (mAbs) isolated from mice immunized with recombinant vesicular stomatitis virus-based filovirus vaccines. Both mAbs recognized the glycoproteins of multiple different ebolaviruses and exhibited broad but differential in vitro neutralization activities against these viruses. By themselves, each mAb provided partial to full protection against Ebola virus in mice, and in combination, the mAbs provided 100% protection against Sudan virus challenge in guinea pigs. This study identified novel mAbs that were elicited through immunization and able to provide protection from ebolavirus infection, thus enriching the pool of candidate therapeutics for treating Ebola disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11009494 | PMC |
| http://dx.doi.org/10.1093/infdis/jiad205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!